W L J van Putten

Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio

E. Vellenga, F. Baron, G. Meloni, 2016, Leukemia.

Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma.

H. Kluin-Nelemans, W. van Putten, P. Lugtenburg, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.